Alliances
MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC, has initiated a phase 3 clinical trial of guselkumab in pediatric patients suffering from chronic plaque psoriasis.
Fermentalg and ADL BioPharma today announced the signing of a long-term manufacturing contract to produce Fermentalg’s algal oil DHA ORIGINS®.
Eli Lilly just signed a license deal with Tokyo’s Chugai Pharmaceutical Co. for OWL833, Chugai’s oral non-peptidic GLP-1 receptor agonist. It is Phase 1-ready being evaluated for type 2 diabetes.
Geron Corporation, located in Menlo Park, Calif., announced that Janssen Biotech, a Johnson & Johnson company, had terminated their 2014 Collaboration and License Agreement.
A three-year-old cancer research alliance between U.S. and Cuban scientists is bearing fruit. A Cuban-developed lung cancer treatment combined with Opdivo shows promise in treating patients.
Quanticate, has announced that it has partnered with CluePoints™ to utilize their software to drive the statistical analysis to perform data integrity checks on all types of monitoring and investigator site data as part of its new Data Quality Oversight service that enables centralized statistical monitoring, in response to the amendments to the ICH Good Clinical Practice (GCP) E6(R2) guidelines.
Cobra Biologics, GE Healthcare and Centre for Process Innovation Collaborate to Advance Gene Therapy
Innovate UK funded project supports development of scalable, cost effective production of regenerative medicines
GlaxoSmithKline (GSK) and the non-profit Aeras reported that their M72/AS01E vaccine candidate significantly cut the rate of pulmonary tuberculosis in HIV-negative adults with latent tuberculosis infection.
Akcea Therapeutics, based in Cambridge, Massachusetts, and Ionis Pharmaceuticals, headquartered in Carlsbad, California, released positive topline data from a Phase II trial of AKCEA-APO(a)-LRx in cardiovascular disease and lipoprotein(a).
Phase 3-ready asset expands VistaGen’s CNS pipeline and complements its neuropsychiatry focus on Major Depressive Disorder (MDD) with AV-101
PRESS RELEASES